Stay updated with breaking news from Shantaram kane. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Megalab gets Rs 300 Cr seed fund to develop Ayurveda-based Covid vaccine yourstory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourstory.com Daily Mail and Mail on Sunday newspapers.
URL copied Image Source : PTI (FILE) Ayurveda-based Covid vaccine could soon become a reality; IIT Alumni Council secures Rs 300 crore funding The IIT Alumni Council-founded Megalab has secured a Rs 300-crore seed funding and is developing a two-dose Ayurveda-based coronavirus vaccine that can stop the spread of the deadly virus and prevent infection within a few days of the first dose. The city-based Megalab, set up last April by the council to drive the fight against the pandemic with ideas and money, will also be importing available vaccines from the West to be distributed first in Mumbai and then elsewhere, the alumni council president Ravi Sharma told PTI on Thursday.
New Delhi: IIT Alumni Council announces fourth generation vaccine with ayurvedic adjuvant under MegaLab initiative. “IIT Alumni Council announces India’s first antigen-free, novel vaccine which is self-limiting, locally manufactured and based on indigenous technology. The preservative-free vaccine is being coupled with an Ayurveda inspired adjuvant which will enhance safety as well as be highly efficacious. The end objective is to deliver a continuously upgradable vaccine which can outpace the virus thus helping to end the pandemic.” said Ravi Sharma, President of the IIT Alumni Council. “We have made remarkable progress globally in understanding vaccines since August 2020. This has helped eliminate many of the vaccine modalities being investigated and we now know that a multi-pronged approach that will elicit an antibody response which neutralises a wide variety of virus mutants is the right target to pursue. Furthermore, the potential ability to access and build upon patented vaccine platform technologies could substantially accelerate development timelines.” added Dr Arindam Bose, a Connecticut based Key Thought Leader of the biotechnology industry, Chairperson of the Therapeutic Group in the C19 Task Force and Senior Advisor to the India Vaccine Stack.